Galectin Therapeutics Inc. (GALT) intrinsic value & 10-year financials
Galectin Therapeutics Inc. (GALT) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.62
- Market cap
- $231.3M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -132.7%
- Free cash flow (FY2025)
- —
GALT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$30.8M | -$0.48 | — | — | 17.3% |
| FY2024 | — | -$47.0M | -$0.76 | — | — | 48.4% |
| FY2023 | — | -$41.1M | -$0.74 | — | — | 58.6% |
| FY2022 | — | -$38.8M | -$0.65 | — | — | 73.9% |
| FY2021 | — | -$30.5M | -$0.52 | — | — | -261.3% |
| FY2020 | — | -$23.5M | -$0.41 | — | — | -70.7% |
| FY2019 | — | -$13.3M | — | — | — | -54.2% |
| FY2018 | — | -$13.9M | — | — | — | -598.5% |
| FY2017 | — | -$16.2M | — | — | — | -332.6% |
| FY2016 | — | -$21.4M | — | — | — | -208.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
GALECTIN THERAPEUTICS INC revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
GALECTIN THERAPEUTICS INC has historically struggled to out-earn its cost of capital, averaging just 5.9% ROIC.
GALECTIN THERAPEUTICS INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
GALECTIN THERAPEUTICS INC is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.